|
1
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei J, Yan Y, Chen X, Qian L, Zeng S, Li
Z, Dai S, Gong Z and Xu Z: The roles of plant-derived Triptolide on
non-small cell lung cancer. Oncol Res. 27:849–858. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ulahannan D, Khalifa J, Faivre-Finn C and
Lee SM: Emerging treatment paradigms for brain metastasis in
non-small-cell lung cancer: An overview of the current landscape
and challenges ahead. Ann Oncol. 28:2923–2931. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou S, Yan Y, Chen X, Wang X, Zeng S,
Qian L, Wei J, Yang X, Zhou Y, Gong Z and Xu Z: Roles of highly
expressed PAICS in lung adenocarcinoma. Gene. 692:1–8. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang R, Sun S, Ji F, Liu C, Lin H, Xie L,
Yang H, Tang W, Zhou Y, Xu J and Li P: CNTN-1 enhances
chemoresistance in human lung adenocarcinoma through induction of
epithelial-mesenchymal transition by targeting the PI3K/Akt
pathway. Cell Physiol Biochem. 43:465–480. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan Y, Su W, Zeng S, Qian L, Chen X, Wei
J, Chen N, Gong Z and Xu Z: Effect and mechanism of tanshinone i on
the radiosensitivity of lung cancer cells. Mol Pharm. 15:4843–4853.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Skerka C, Chen Q, Fremeaux-Bacchi V and
Roumenina LT: Complement factor H related proteins (CFHRs). Mol
Immunol. 56:170–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rogers LM, Mott SL, Smith BJ, Link BK,
Sahin D and Weiner GJ: Complement-regulatory proteins CFHR1 and
CFHR3 and patient response to anti-CD20 monoclonal antibody
therapy. Clin Cancer Res. 23:954–961. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hageman GS, Hancox LS, Taiber AJ, Gehrs
KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A,
Atkinson J, et al: Extended haplotypes in the complement factor H
(CFH) and CFH-related (CFHR) family of genes protect against
age-related macular degeneration: Characterization, ethnic
distribution and evolutionary implications. Ann Med. 38:592–604.
2006. View Article : Google Scholar :
|
|
10
|
Jullien P, Laurent B, Claisse G, Masson I,
Dinic M, Thibaudin D, Berthoux F, Alamartine E, Mariat C and
Maillard N: Deletion Variants of CFHR1 and CFHR3
associate with mesangial immune deposits but not with progression
of IgA nephropathy. J Am Soc Nephrol. 29:661–669. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fratelli M, Bolis M, Kurosaki M, Dori M,
Guarnaccia V, Spinelli O, Alberti M, Valoti E, Pileggi S, Noris M,
et al: Association of CFHR1 homozygous deletion with acute
myelogenous leukemia in the European population. Leuk Lymphoma.
57:1234–1237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cui L, Fu J, Pang JC, Qiu ZK, Liu XM, Chen
FR, Shi HL, Ng HK and Chen ZP: Overexpression of IL-7 enhances
cisplatin resistance in glioma. Cancer Biol Ther. 13:496–503. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lánczky A, Nagy Á, Bottai G, Munkácsy G,
Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to
validate survival-associated miRNAs utilizing expression data from
2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan Y, Xu Z, Hu X, Qian L, Li Z, Zhou Y,
Dai S, Zeng S and Gong Z: SNCA is a functionally low-expressed gene
in lung adenocarcinoma. Genes (Basel). 9:E162018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Lecane PS, Thiemann P, Fan Q,
Cortez C, Ma X, Tonev D, Miles D, Naumovski L, Miller RA, et al:
Synthesis and biologic properties of hydrophilic sapphyrins, a new
class of tumor-selective inhibitors of gene expression. Mol Cancer.
6:92007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun Y, Zheng S, Torossian A, Speirs CK,
Schleicher S, Giacalone NJ, Carbone DP, Zhao Z and Lu B: Role of
insulin-like growth factor-1 signaling pathway in
cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol
Phys. 82:e563–e572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su G, Morris JH, Demchak B and Bader GD:
Biological network exploration with Cytoscape 3. Curr Protoc
Bioinformatics. 47:8.13.1–24. 2014. View Article : Google Scholar
|
|
23
|
Wang J, Vasaikar S, Shi Z, Greer M and
Zhang B: WebGestalt 2017: A more comprehensive, powerful, flexible
and interactive gene set enrichment analysis toolkit. Nucleic Acids
Res. 45:W130–W137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo W, Pant G, Bhavnasi YK, Blanchard SG
Jr and Brouwer C: Pathview Web: User friendly pathway visualization
and data integration. Nucleic Acids Res. 45:W501–W508. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhattacharjee A, Richards WG, Staunton J,
Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et
al: Classification of human lung carcinomas by mRNA expression
profiling reveals distinct adenocarcinoma subclasses. Proc Natl
Acad Sci USA. 98:13790–13795. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beer DG, Kardia SL, Huang CC, Giordano TJ,
Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al:
Gene-expression profiles predict survival of patients with lung
adenocarcinoma. Nat Med. 8:816–824. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou H, Vallieres M, Bai HX, Su C, Tang H,
Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, et al: MRI features
predict survival and molecular markers in diffuse lower-grade
gliomas. Neuro Oncol. 19:862–870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hannan JP, Laskowski J, Thurman JM,
Hageman GS and Holers VM: Mapping the complement factor H-related
protein 1 (CFHR1):C3b/C3d interactions. PLoS One. 11:e01662002016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Trojnar E, Józsi M, Uray K, Csuka D,
Szilágyi Á, Milosevic D, Stojanović VD, Spasojević B, Rusai K,
Müller T, et al: Analysis of linear antibody epitopes on factor H
and CFHR1 using sera of patients with autoimmune atypical hemolytic
uremic syndrome. Front Immunol. 8:3022017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Valoti E, Alberti M, Tortajada A,
Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G,
Rodriguez de Cordoba S and Noris M: A novel atypical hemolytic
uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion
protein that antagonizes factor H-dependent complement regulation.
J Am Soc Nephrol. 26:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guo X, Hao Y, Kamilijiang M, Hasimu A,
Yuan J, Wu G, Reyimu H, Kadeer N and Abudula A: Potential
predictive plasma biomarkers for cervical cancer by 2D-DIGE
proteomics and ingenuity pathway analysis. Tumour Biol.
36:1711–1720. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arya SK and Estrela P: Electrochemical
ELISA-based platform for bladder cancer protein biomarker detection
in urine. Biosens Bioelectron. 117:620–627. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Charbonneau B, Maurer MJ, Fredericksen ZS,
Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig
TE, et al: Germline variation in complement genes and event-free
survival in follicular and diffuse large B-cell lymphoma. Am J
Hematol. 87:880–885. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jullien P, Laurent B, Claisse G, Masson I,
Dinic M, Thibaudin D, Berthoux F, Alamartine E, Mariat C and
Maillard N: Deletion variants of CFHR1 and CFHR3 associate with
mesangial immune deposits but not with progression of IgA
nephropathy. J Am Soc Nephrol. 29:661–669. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lamano JB, Lamano JB, Li YD, DiDomenico
JD, Choy W, Veliceasa D, Oyon DE, Fakurnejad S, Ampie L,
Kesavabhotla K, et al: Glioblastoma-derived IL6 induces
immunosuppressive peripheral myeloid cell PD-L1 and promotes tumor
growth. Clin Cancer Res. 25:3643–3657. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bustelo XR and Dosil M: Ribosome
biogenesis and cancer: basic and translational challenges. Curr
Opin Genet Dev. 48:22–29. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
de la Cruz J, Gómez-Herreros F,
Rodríguez-Galán O, Begley V, de la Cruz Muñoz-Centeno M and Chávez
S: Feedback regulation of ribosome assembly. Curr Genet.
64:393–404. 2018. View Article : Google Scholar : PubMed/NCBI
|
